Tenax Therapeutics reports Q2 GAAP EPS of -$0.35 Tenax Therapeutics reported a Q2 GAAP EPS of -$0.35, beating estimates by $0.01. The company's cash and cash equivalents stood at $118.0 million as of June 30, 2026. Proceeds of $13.4 million were generated during
Tenax Therapeutics reports Q2 GAAP EPS of -$0.35
Tenax Therapeutics reported a Q2 GAAP EPS of -$0.35, beating estimates by $0.01.
The company’s cash and cash equivalents stood at $118.0 million as of June 30, 2026.
Proceeds of $13.4 million were generated during the second quarter from exercises of previously issued warrants.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
